Queensland Clinical Guidelines

Translating evidence into best clinical practice

Maternity and Neonatal Clinical Guideline

Guideline Supplement: Early pregnancy loss



Table of Contents

1	Intro	ductionduction	3
	1.1	Funding	.3
	1.2	Conflict of interest	.3
	1.3	Development process	3
	1.4	Summary of changes	4
2	Meth	odology	5
	2.1	Topic identification	5
	2.2	Scope	5
	2.3	Clinical questions	
	2.4	Search strategy	6
	2.4.1	Keywords	6
	2.5	Consultation	7
	2.6	Endorsement	7
	2.7	Citation	7
3	Leve	ls of evidence Use from applicable evidence source	8
	3.1	Summary recommendations	
4	Imple	ementation	9
	4.1	Guideline resources	9
	4.2	Suggested resources	9
	4.3	Implementation measures	9
	4.3.1	QCG measures	9
	4.3.2	Hospital and Health Service measures	9
	4.3.3	Implications for implementation	9
	4.4	Quality measures1	0
	4.5	Areas for future research	
	4.6	Safety and quality1	1
R	eference	es1	
	ist of Ta		
		Summary of change	
		Scope framework	
		Basic search strategy	
		Major guideline development processes	
		NSQHS Standard 1	
		Clinical quality measures	
		Jeone	

© State of Queensland (Queensland Health) 2022



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For further information contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au, For permissions beyond the scope of this licence contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip officer@health.gld.gov.au

1 Introduction

This document is a supplement to the Queensland Clinical Guideline (QCG) Early pregnancy loss. It provides supplementary information regarding guideline development, makes summary recommendations, suggests measures to assist implementation and quality activities and summarises changes (if any) to the guideline since original publication. Refer to the guideline for abbreviations, acronyms, flow charts and acknowledgements.

1.1 Funding

The development of this guideline was funded by Healthcare Improvement Unit, Queensland Health. Consumer representatives were paid a standard fee. Other working party members participated on a voluntary basis.

1.2 Conflict of interest

Declarations of conflict of interest were sought from working party members as per the Queensland Clinical Guidelines *Conflict of Interest* statement. No conflict of interest was identified.

1.3 Development process

This version of the guideline followed the Queensland Clinical Guideline Peer review process

1.4 Summary of changes

Queensland clinical guidelines are reviewed every 5 years or earlier if significant new evidence emerges. Table 1 provides a summary of changes made to the guidelines since original publication.

Table 1. Summary of change

Publication date Endorsed by:	Identifier	Summary of major change
September 2011 MN11.29-V1-R16 First publication		First publication
March 2015	 Updated Section 9: Details of Queensland Trophoblast Centre (QTC) MN11.29-V2-R16 Updated contact details of Appendix C: Support Contacts Formatting updates including name change and branding 	
 Revised recommendation at Table 10, Row 1 (Prior to commencement): From: Advise loading with Sodium Citrotartrate (as sachets) or IV 8.4%Sodium Bicarbonate hour To: Advise loading with Sodium Citrotartrate (as sachets) 		From: Advise loading with Sodium Citrotartrate (as sachets) or IV 8.4%Sodium Bicarbonate in 100mls over 1 hour
May 2017 Statewide Maternity and Neonatal Clinical Network Neonatal Clinical Network		First full review
 May 2018 MN17.29-V5-R22 From: USS not routinely recommended To: Repeat USS in one week and thereafter as clinically in MFM for follow-up—direct injection of potassium chloride in Minor corrections to reference list 		To: Repeat USS in one week and thereafter as clinically indicated. If fetal heart present on USS, refer urgently to MFM for follow-up—direct injection of potassium chloride may be indicated
 Queensland Maternity and Neonatal Clinical Network MN22.29-V6-R27 Added: Predictive models for PUL 		 Content relevant to Queensland Clinical Guideline: Standard care removed References and formatting updated Added:

2 Methodology

Queensland Clinical Guidelines (QCG) follows a rigorous process of guideline development. This process was endorsed by the Queensland Health Patient Safety and Quality Executive Committee in December 2009. The guidelines are best described as 'evidence informed consensus guidelines' and draw from the literature, the evidence base of existing national and international guidelines and the expert opinion of the working party.

2.1 Topic identification

Development of this guideline was requested by Department of Health, Queensland in 2011

2.2 Scope

The scope of the guideline was determined using the following framework.

Table 2. Scope framework

Scope framewo	Scope framework			
Population	n Pregnant women experiencing or at risk of pregnancy loss before 20 weeks			
Purpose	Identify relevant evidence related to pregnancy loss before 20 weeks: • Diagnosis by type • Assessment • Management			
Outcome Support evidence informed: Assessment of women at risk of early pregnancy loss Diagnosis of type of early pregnancy loss Investigations to confirm diagnosis Identification of treatment relevant to type of early pregnancy loss Psychological support for the woman/family				
Termination of pregnancy Pregnancy loss after 20 weeks Management of anaesthesia Usual or standard care outlined in the Queensland Clinical Guideline Standard care				

2.3 Clinical questions

The following clinical questions were generated to inform the guideline scope and purpose:

- What are the types of early pregnancy loss and how are they diagnosed?
- What management is recommended for each type of EPL?
- What care is recommended during and following early pregnancy loss?

2.4 Search strategy

A search of the literature was conducted during January 2022–May 2022. The QCG search strategy is an iterative process that is repeated and amended as guideline development occurs (e.g. if additional areas of interest emerge, areas of contention requiring more extensive review are identified or new evidence is identified). All guidelines are developed using a basic search strategy. This involves both a formal and informal approach.

Table 3. Basic search strategy

Step		Consideration	
Review clinical guidelines developed by other reputable groups relevant to the clinical speciality		 This may include national and/or international guideline writers, professional organisations, government organisations, state based groups. This assists the guideline writer to identify: The scope and breadth of what others have found useful for clinicians and informs the scope and clinical question development Identify resources commonly found in guidelines such as flowcharts, audit criteria and levels of evidence Identify common search and key terms Identify common and key references 	
2.	Undertake a foundation search using key search terms	Construct a search using common search and key terms identified during Step 1 above Search the following databases PubMed CINAHL Medline Cochrane Central Register of Controlled Trials EBSCO Embase Studies published in English less than or equal to 5 years previous are reviewed in the first instance. Other years may be searched as are relevant to the topic Save and document the search Add other databases as relevant to the clinical area	
3.	Develop search word list for each clinical question	 This may require the development of clinical sub-questions beyond those identified in the initial scope. Using the foundation search performed at Step 2 as the baseline search framework, refine the search using the specific terms developed for the clinical question Save and document the search strategy undertaken for each clinical question 	
4.	Other search strategies	 Search the reference lists of reports and articles for additional studies Access other sources for relevant literature Known resource sites Internet search engines Relevant textbooks 	

2.4.1 Keywords

The following keywords were used in the basic search strategy:

Early pregnancy loss, pregnancy loss, miscarriage, ectopic, ectopic pregnancy, threatened abortion, threatened miscarriage, missed abortion, missed miscarriage, incomplete abortion, incomplete miscarriage, complete abortion, complete miscarriage, spontaneous abortion, spontaneous miscarriage, blighted ovum, anembryonic pregnancy, failed intrauterine pregnancy, tubal pregnancy, second trimester loss, second trimester pregnancy loss, GTD, molar pregnancy, partial molar pregnancy, complete hydatidiform mole, partial hydatidiform mole, gestational trophoblastic disease

Other keywords may have been used for specific aspects of the guideline.

2.5 Consultation

Major consultative and development processes occurred between June 2022 and August 2022.

Table 4. Major guideline development processes

Process	Activity	
Original development	 Last full consultation and development processes occurred in 2017 This included formation of a working party and statewide consultation as per usual QCG process 	
Decision for peer review	 A review of the guideline scope, clinical questions and current literature was undertaken in May 2022 and areas of clinical practice change were identified Clinical leads Reviewed the previous scope and version of the guideline Reviewed identified areas of clinical practice change Confirmed aspects of the guideline for update and new inclusions Reached consensus agreement that a peer review process was appropriate 	
Consultation	 Expert clinicians and a consumer representative were identified by the clinical leads and invited to peer review the updated guideline in July 2022 All invited members accepted 	

2.6 Endorsement

The guideline was endorsed by the:

- Queensland Clinical Guidelines Steering Committee in September 2022
- Queensland Maternity and Neonatal Clinical Network in October 2022

2.7 Citation

The recommended citation of Queensland Clinical Guidelines is in the following format:

Queensland Clinical Guidelines. [Insert Guideline Title]. Guideline No. [Insert Guideline Number]. Queensland Health. [Insert Year of Publication]. Available from: www.health.qld.gov.au/qcg.

EXAMPLE:

Queensland Clinical Guidelines. Normal birth. Guideline No. MN17.25-V3-R22. Queensland Health 2017. Available from: www.health.qld.gov.au/qcg.

3 Levels of evidence Use from applicable evidence source

Summary consensus recommendations were informed by:

- Review of literature
- Expertise and experience of clinical leads and working party
- Statewide consultation
- Established Queensland Clinical Guidelines development process

3.1 Summary recommendations

Summary recommendations and levels of evidence are outlined in Table 5. Summary recommendations.

Table 5. Summary recommendations

Reco	Recommendation Grading of evidence			
1.	Offer women experiencing early pregnancy loss, all options for care that are clinically appropriate to their individual circumstances	Consensus		
2.	Perform a serum pregnancy test on all women of reproductive age presenting with a history of pain (abdominal, shoulder tip) and/or, vaginal bleeding	Consensus		
3.	Register all women experiencing gestational trophoblastic disease with the Queensland Trophoblast Centre	Consensus		
4.	Recommend Rh D immunoglobulin to Rh D negative women (without preformed anti-D antibodies) who experience an early pregnancy loss (including ectopic pregnancy)	Consensus		
5.	Consistently apply agreed diagnostic criteria to assess viability of an intrauterine pregnancy	Consensus		
6.	Offer women experiencing early pregnancy loss psychological support and follow- up	Consensus		

4 Implementation

This guideline is applicable to all Queensland public and private maternity facilities. It can be downloaded in Portable Document Format (PDF) from www.health.qld.gov.au/qcg

4.1 Guideline resources

The following guideline components are provided on the website as separate resources:

- Flowchart: assessment of suspected early pregnancy loss
- Education resource: Early pregnancy loss
- Knowledge assessment: Early pregnancy loss
- Patient information:
 - Pain and bleeding in early pregnancy
 - Ectopic pregnancy
 - o Methotrexate for ectopic pregnancy
 - o After a miscarriage

4.2 Suggested resources

During the development process stakeholders identified additional resources with potential to complement and enhance guideline implementation and application. The following resources have not been sourced or developed by QCG but are suggested as complimentary to the guideline:

- Standardised form for documentation of results of ultrasound scan
- Local protocols for the timing of repeat/confirmatory USS when diagnosis uncertain
- Local protocols to facilitate sensitive disposal of fetal remains

4.3 Implementation measures

Suggested activities to assist implementation of the guideline are outlined below.

4.3.1 QCG measures

- Notify Chief Executive Officer and relevant stakeholders
- Monitor emerging new evidence to ensure guideline reflects contemporaneous practice
- Capture user feedback
- Record and manage change requests

4.3.2 Hospital and Health Service measures

Initiate, promote and support local systems and processes to integrate the guideline into clinical practice, including:

- Hospital and Health Service (HHS) Executive endorse the guidelines and their use in the HHS and communicate this to staff
- Promote the introduction of the guideline to relevant health care professionals
- Support education and training opportunities relevant to the guideline and service capabilities
- Align clinical care with guideline recommendations
- Undertake relevant implementation activities as outlined in the *Guideline implementation* checklist available at www.health.qld.gov.au/qcg

4.3.3 Implications for implementation

The following areas may have implications for local implementation of the guideline recommendations. It is suggested they be considered for successful guideline implementation.

- Economic considerations including opportunity costs
- Human resource requirements including clinician skill mix and scope of practice
- · Clinician education and training
- Equipment and consumables purchase and maintenance
- Consumer acceptance
- Model of care and service delivery

4.4 Quality measures

Auditing of guideline recommendations and content assists with identifying quality of care issues and provides evidence of compliance with the National Safety and Quality Health Service (NSQHS)Standards¹ [Refer to Table 6. NSQHS Standard 1]. Suggested audit and quality measures are identified in Table 7. Clinical quality measures.

Table 6. NSQHS Standard 1

NSQHS Standard 1: Clinical governance			
Clinical performance and effectiveness			
Criterion 1.27:	Actions required:		
Evidence based care	Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice		
Evidence based care	b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care		

The following clinical quality measures are suggested:

Table 7. Clinical quality measures

No	Audit criteria	Guideline Section
1.	The proportion of women diagnosed with Gestational Trophoblastic Disease who were referred to the Queensland Trophoblast Centre (GTC)	Section 7 Gestational trophoblastic disease
2.	Proportion of Rh D negative women (without preformed anti- D antibodies) offered Rh D immunoglobulin following an early pregnancy loss	Section 2 Principles of EPL care
3.	The proportion of women having non-surgical management (i.e. medical or expectant management) with histopathology of products of conception	Section 2: Principles of EPL care
4.	The experiences of women who receive care for early pregnancy loss	All section (particularly Section 2.1 Psychological support)

4.5 Areas for future research

During development the following areas where identified as having limited or poor quality evidence to inform clinical decision making. Further research in these areas may be useful.

- Investigations for recurrent pregnancy loss
- Refinement of risk stratification models for pregnancy of unknown location for local context

4.6 Safety and quality

In conjunction with the Queensland Clinical Guideline *Standard care*², implementation of this guideline provides evidence of compliance with the National Safety and Quality Health Service Standards.¹

Table 8. NSQHS

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 1: Clinical governance			
Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.	Diversity and high risk groups 1.15 The health service organisation: a. Identifies the diversity of the consumers using its services b. Identifies groups of patients using its services who are at higher risk of harm c. Incorporates information on the diversity of its consumers and higher-risk groups into the planning and delivery of care	 ✓ Assessment and care appropriate to the cohort of patients is identified in the guideline ✓ High risk groups are identified in the guideline ✓ The guideline is based on the best available evidence 	
Clinical performance and effectiveness The workforce has the right qualifications, skills and supervision to	Evidence based care 1.27 The health service organisation has processes that: a. Provide clinicians with ready access to best-practice guidelines, integrated care pathways, clinical pathways and decision support tools relevant to their clinical practice b. Support clinicians to use the best available evidence, including relevant clinical care standards developed by the Australian Commission on Safety and Quality in Health Care	 Queensland Clinical Guidelines is funded by Queensland Health to develop clinical guidelines relevant to the service line to guide safe patient care across Queensland The guideline provides evidence-based and best practice recommendations for care The guideline is endorsed for use in Queensland Health facilities. A desktop icon is available on every Queensland Health computer desktop to provide quick and easy access to the guideline 	
provide safe, high-quality health care to patients.	Performance management 1.22 The health service organisation has valid and reliable performance review processes that: a. Require members of the workforce to regularly take part in a review of their performance b. Identify needs for training and development in safety and quality c. Incorporate information on training requirements into the organisation's training system	☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet http://www.health.qld.gov.au/qcg	

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 1: Clinical governance			
Patient safety and quality systems Safety and quality systems are integrated with governance processes to enable organisations to actively manage and improve the safety and quality of health care for patients.	Policies and procedures 1.7 The health service organisation uses a risk management approach to: a. Set out, review, and maintain the currency and effectiveness of, policies, procedures and protocols b. Monitor and take action to improve adherence to policies, procedures and protocols c. Review compliance with legislation, regulation and jurisdictional requirements	 ☑ QCG has established processes to review and maintain all guidelines and associated resources ☑ Change requests are managed to ensure currency of published guidelines ☑ Implementation tools and checklist are provided to assist with adherence to guidelines ☑ Suggested audit criteria are provided in guideline supplement ☑ The guidelines comply with legislation, regulation and jurisdictional requirements 	
NSQHS Standard 2: Partnering with Co			
Health literacy Health service organisations communicate with consumers in a way that supports effective partnerships.	Communication that supports effective partnerships 2.8 The health service organisation uses communication mechanisms that are tailored to the diversity of the consumers who use its services and, where relevant, the diversity of the local community 2.9 Where information for patients, carers, families and consumers about health and health services is developed internally, the organisation involves consumers in its development and review 2.10 The health service organisation supports clinicians to communicate with patients, carers, families and consumers about health and health care so that: a. Information is provided in a way that meets the needs of patients, carers, families and consumers b. Information provided is easy to understand and use c. The clinical needs of patients are addressed while they are in the health service organisation d. Information needs for ongoing care are provided on discharge	 ✓ Consumer consultation was sought and obtained during the development of the guideline. Refer to the acknowledgement section of the guideline for details ✓ Consumer information is developed to align with the guideline and included consumer involvement during development and review ✓ The consumer information was developed using plain English and with attention to literacy and ease of reading needs of the consumer 	
Partnering with consumers in organisational design and governance Consumers are partners in the design and governance of the organisation.	Partnerships in healthcare governance planning, design, measurement and evaluation 2.11 The health service organisation: a. Involves consumers in partnerships in the governance of, and to design, measure and evaluate, health care b. Has processes so that the consumers involved in these partnerships reflect the diversity of consumers who use the service or, where relevant, the diversity of the local community 2.14 The health service organisation works in partnership with consumers to incorporate their views and experiences into training and education for the workforce	 ☑ Consumers are members of guideline working parties ☑ The guideline is based on the best available evidence ☑ The guidelines and consumer information are endorsed by the QCG and Queensland Statewide Maternity and Neonatal Clinical Network Steering Committees which includes consumer membership 	

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 4: Medication safety			
Clinical governance and quality improvement to support medication management Organisation-wide systems are used to support and promote safety for procuring, supplying, storing, compounding, manufacturing, prescribing, dispensing, administering and monitoring the effects of medicines	Integrating clinical governance 4.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for medication management b. Managing risks associated with medication management c. Identifying training requirements for medication management	☑ The guideline provides current evidence based recommendations about medication	
NSQHS Standard 5: Comprehensive ca	are		
Clinical governance and quality improvement to support comprehensive care Systems are in place to support clinicians to deliver comprehensive care	Integrating clinical governance 5.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for comprehensive care b. Managing risks associated with comprehensive care c. Identifying training requirements to deliver comprehensive care Partnering with consumers 5.3 Clinicians use organisational processes from the Partnering with Consumers Standard when providing comprehensive care to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making	 ☑ The guideline has accompanying educational resources to support ongoing safety and quality education for identified professional and personal development. The resources are freely available on the internet http://www.health.qld.gov.au/qcg ☑ The guideline provides evidence-based and best practice recommendations for care ☑ Consumer information is developed for the guideline 	

NSQHS Criteria	Actions required	☑ Evidence of compliance	
NSQHS Standard 6: Communicating for	or safety		
Clinical governance and quality improvement to support effective communication Systems are in place for effective and coordinated communication that supports the delivery of continuous and safe care for patients.	Integrating clinical governance 6.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures to support effective clinical communication b. Managing risks associated with clinical communication c. Identifying training requirements for effective and coordinated clinical communication Partnering with consumers 6.3 Clinicians use organisational processes from the Partnering with Consumers Standard to effectively communicate with patients, carers and families during high-risk situations to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making Organisational processes to support effective communication 6.4 The health service organisation has clinical communications processes to support effective communication when: a. Identification and procedure matching should occur b. All or part of a patient's care is transferred within the organisation, between multidisciplinary teams, between clinicians or between organisations; and on discharge c. Critical information about a patient's care, including information on risks, emerges or changes	 ☑ Requirements for effective clinical communication by clinicians are identified ☑ The guideline provides evidence-based and best practice recommendations for communication between clinicians ☑ The guideline provides evidence-based and best practice recommendations for communication with patients, carers and families ☑ The guideline provides evidence-based and best practice recommendations for discharge planning and follow –up care 	
Communication of critical information Systems to effectively communicate critical information and risks when they emerge or change are used to ensure safe patient care.	Communicating critical information 6.9 Clinicians and multidisciplinary teams use clinical communication processes to effectively communicate critical information, alerts and risks, in a timely way, when they emerge or change to: a. Clinicians who can make decisions about care b. Patients, carers and families, in accordance with the wishes of the patient 6.10 The health service organisation ensures that there are communication processes for patients, carers and families to directly communicate critical information and risks about care to clinicians	 ☑ Requirements for effective clinical communication of critical information are identified ☑ Requirements for escalation of care are identified 	

NSQHS Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 6: Communicating for safety (continued)				
Correct identification and procedure matching Systems to maintain the identity of the patient are used to ensure that the patient receives the care intended for them.	Correct identification and procedure matching 6.5 The health service organisation: a. Defines approved identifiers for patients according to best- practice guidelines b. Requires at least three approved identifiers on registration and admission; when care, medication, therapy and other services are provided; and when clinical handover, transfer or discharge documentation is generated	☑ Requirements for safe and for correct patient identification are identified		
Communicating at clinical handover Processes for structured clinical handover are used to effectively communicate about the health care of patients.	Clinical handover 6.7 The health service organisation, in collaboration with clinicians, defines the: a. Minimum information content to be communicated at clinical handover, based on best-practice guidelines b. Risks relevant to the service context and the particular needs of patients, carers and families c. Clinicians who are involved in the clinical handover 6.8 Clinicians use structured clinical handover processes that include: a. Preparing and scheduling clinical handover b. Having the relevant information at clinical handover c. Organising relevant clinicians and others to participate in clinical handover d. Being aware of the patient's goals and preferences e. Supporting patients, carers and families to be involved in clinical handover, in accordance with the wishes of the patient f. Ensuring that clinical handover results in the transfer of responsibility and accountability for care	☐ The guideline acknowledges the need for local protocols to support transfer of information, professional responsibility and accountability for some or all aspects of care		

NSQHSI Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 7: Blood management				
Clinical governance and quality improvement to support blood management Organisation-wide governance and quality improvement systems are used to ensure safe and high-quality care of patients' own blood, and to ensure that blood product requirements are met.	Integrating clinical governance 7.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for blood management b. Managing risks associated with blood management c. Identifying training requirements for blood management	☑ The guideline provides evidence-based and best practice recommendations for use of blood products		
Prescribing and clinical use of blood and blood products The clinical use of blood and blood products is appropriate, and strategies are used to reduce the risks associated with transfusion.	Optimising and conserving patients' own blood 7.4 Clinicians use the blood and blood products processes to manage the need for, and minimise the inappropriate use of, blood and blood products by: a. Optimising patients' own red cell mass, haemoglobin and iron stores b. Identifying and managing patients with, or at risk of, bleeding c. Determining the clinical need for blood and blood products, and related risks Prescribing and administering blood and blood products 7.6 The health service organisation supports clinicians to prescribe and administer blood and blood products appropriately, in accordance with national guidelines and national criteria	 ☑ The guideline provides evidence-based and best practice recommendations for use of blood products ☑ The guideline is consistent with recommendations of national guidelines 		

NSQHS Criteria	Actions required	☑ Evidence of compliance		
NSQHS Standard 8: Recognising and responding to acute deterioration				
Clinical governance and quality improvement to support recognition and response systems Organisation-wide systems are used to support and promote detection and recognition of acute deterioration, and the response to patients whose condition acutely deteriorates.	Integrating clinical governance 8.1 Clinicians use the safety and quality systems from the Clinical Governance Standard when: a. Implementing policies and procedures for recognising and responding to acute deterioration b. Managing risks associated with recognising and responding to acute deterioration c. Identifying training requirements for recognising and responding to acute deterioration Partnering with consumers 8.3 Clinicians use organisational processes from the Partnering with Consumers Standard when recognising and responding to acute deterioration to: a. Actively involve patients in their own care b. Meet the patient's information needs c. Share decision-making Recognising acute deterioration 8.4 The health service organisation has processes for clinicians to detect acute physiological deterioration that require clinicians to: a. Document individualised vital sign monitoring plans b. Monitor patients as required by their individualised monitoring plan c. Graphically document and track changes in agreed observations to detect acute deterioration over time, as appropriate for the patient	 ☑ The guideline is consistent with National Consensus statements recommendations ☑ The guideline recommends use of tools consistent with the principles of recognising and responding to clinical deterioration ☑ Consumer information is developed for the guideline 		

References

- 1. Australian Commission on Safety and Quality in Health Care. National safety and quality health service standards [Internet]. 2017 [cited 2022 May 09]. Available from: http://www.safetyandquality.gov.au.
- Queensland Clinical Guidelines. Standard care. Guideline No. MN18.50-V1-R23. [Internet].
 Queensland Health. 2018. [cited 2022 April 12]. Available from: https://www.health.qld.gov.au/qcg.